ID   PGFRA_HUMAN             Reviewed;        1089 AA.
AC   P16234; B2RE69; E9PBH0; Q6P4H5; Q96KZ7; Q9UD28;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   12-OCT-2022, entry version 237.
DE   RecName: Full=Platelet-derived growth factor receptor alpha;
DE            Short=PDGF-R-alpha;
DE            Short=PDGFR-alpha;
DE            EC=2.7.10.1;
DE   AltName: Full=Alpha platelet-derived growth factor receptor;
DE   AltName: Full=Alpha-type platelet-derived growth factor receptor;
DE   AltName: Full=CD140 antigen-like family member A;
DE   AltName: Full=CD140a antigen;
DE   AltName: Full=Platelet-derived growth factor alpha receptor;
DE   AltName: Full=Platelet-derived growth factor receptor 2;
DE            Short=PDGFR-2;
DE   AltName: CD_antigen=CD140a;
DE   Flags: Precursor;
GN   Name=PDGFRA; Synonyms=PDGFR2, RHEPDGFRA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH PDGFA AND
RP   PDGFB.
RC   TISSUE=Foreskin;
RX   PubMed=2544881; DOI=10.1073/pnas.86.13.4917;
RA   Claesson-Welsh L., Eriksson A., Westermark B., Heldin C.H.;
RT   "cDNA cloning and expression of the human A-type platelet-derived growth
RT   factor (PDGF) receptor establishes structural similarity to the B-type PDGF
RT   receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:4917-4921(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AUTOPHOSPHORYLATION, TISSUE
RP   SPECIFICITY, AND INTERACTION WITH PDGFA AND PDGFB.
RC   TISSUE=Brain;
RX   PubMed=2536956; DOI=10.1126/science.2536956;
RA   Matsui T., Heidaran M., Miki T., Popescu N., la Rochelle W., Kraus M.,
RA   Pierce J., Aaronson S.;
RT   "Isolation of a novel receptor cDNA establishes the existence of two PDGF
RT   receptor genes.";
RL   Science 243:800-804(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8586421; DOI=10.1006/geno.1995.9883;
RA   Kawagishi J., Ku T.;
RT   "Structure, organization, and transcription units of the human alpha-
RT   platelet-derived growth factor receptor gene, PDGFRA.";
RL   Genomics 30:224-232(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PRO-478.
RC   TISSUE=Lung, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND VARIANT
RP   PRO-478.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 579-1089, DISEASE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY OF FIP1L1-PDGFRA FUSION PROTEIN.
RC   TISSUE=Eosinophil;
RX   PubMed=12808148; DOI=10.1073/pnas.0932698100;
RA   Griffin J.H., Leung J., Bruner R.J., Caligiuri M.A., Briesewitz R.;
RT   "Discovery of a fusion kinase in EOL-1 cells and idiopathic
RT   hypereosinophilic syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7830-7835(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 823-876, AND TISSUE SPECIFICITY.
RC   TISSUE=Colon tumor;
RX   PubMed=7896447; DOI=10.1002/ijc.2910600611;
RA   Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A., Srivastava S.,
RA   Varnum B., Liu E.T., Cance W.G.;
RT   "Receptor tyrosine kinases expressed in metastatic colon cancer.";
RL   Int. J. Cancer 60:791-797(1995).
RN   [9]
RP   FUNCTION AS PDGFA AND PDGFB RECEPTOR IN CELL PROLIFERATION AND CHEMOTAXIS,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=2554309; DOI=10.1073/pnas.86.21.8314;
RA   Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S., LaRochelle W.J.,
RA   Ruggiero M., Aaronson S.A.;
RT   "Independent expression of human alpha or beta platelet-derived growth
RT   factor receptor cDNAs in a naive hematopoietic cell leads to functional
RT   coupling with mitogenic and chemotactic signaling pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989).
RN   [10]
RP   INTERACTION WITH PLCG1 AND SRC.
RX   PubMed=2173144; DOI=10.1126/science.2173144;
RA   Anderson D., Koch C.A., Grey L., Ellis C., Moran M.F., Pawson T.;
RT   "Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to
RT   activated growth factor receptors.";
RL   Science 250:979-982(1990).
RN   [11]
RP   INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR PDGFA
RP   AND PDGFB, AND AUTOPHOSPHORYLATION.
RX   PubMed=1709159; DOI=10.1016/s0021-9258(18)31541-2;
RA   Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A.,
RA   Bowen-Pope D.F., Cooper J.A., Kazlauskas A.;
RT   "Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit
RT   dimerization and intersubunit trans-phosphorylation.";
RL   J. Biol. Chem. 266:8987-8992(1991).
RN   [12]
RP   FUNCTION AS PDGFB RECEPTOR IN CHEMOTAXIS; CELL PROLIFERATION;
RP   PHOSPHORYLATION OF PLCG1; ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE AND
RP   REGULATION OF PHOSPHATIDYLINOSITOL METABOLISM, INTERACTION WITH PIK3R,
RP   PHOSPHORYLATION AT TYR-731 AND TYR-742, AND MUTAGENESIS OF TYR-731 AND
RP   TYR-742.
RX   PubMed=1646396; DOI=10.1128/mcb.11.7.3780-3785.1991;
RA   Yu J.C., Heidaran M.A., Pierce J.H., Gutkind J.S., Lombardi D.,
RA   Ruggiero M., Aaronson S.A.;
RT   "Tyrosine mutations within the alpha platelet-derived growth factor
RT   receptor kinase insert domain abrogate receptor-associated
RT   phosphatidylinositol-3 kinase activity without affecting mitogenic or
RT   chemotactic signal transduction.";
RL   Mol. Cell. Biol. 11:3780-3785(1991).
RN   [13]
RP   INTERACTION WITH PDGFA AND PDGFB.
RX   PubMed=7679113; DOI=10.1016/s0021-9258(18)53739-x;
RA   Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L.,
RA   LaRochelle W.J., Giese N.A.;
RT   "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding
RT   to alpha and beta PDGF receptor.";
RL   J. Biol. Chem. 268:3625-3631(1993).
RN   [14]
RP   FUNCTION AS PDGFA RECEPTOR IN REGULATION OF PLATELET ACTIVATION,
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=8188664; DOI=10.1016/s0021-9258(17)36728-5;
RA   Vassbotn F.S., Havnen O.K., Heldin C.H., Holmsen H.;
RT   "Negative feedback regulation of human platelets via autocrine activation
RT   of the platelet-derived growth factor alpha-receptor.";
RL   J. Biol. Chem. 269:13874-13879(1994).
RN   [15]
RP   PHOSPHORYLATION AT TYR-988 AND TYR-1018, AND INTERACTION WITH PLCG1.
RX   PubMed=7535778; DOI=10.1074/jbc.270.13.7773;
RA   Eriksson A., Naanberg E., Roennstrand L., Engstroem U., Hellman U.,
RA   Rupp E., Carpenter G., Heldin C.H., Claesson-Welsh L.;
RT   "Demonstration of functionally different interactions between phospholipase
RT   C-gamma and the two types of platelet-derived growth factor receptors.";
RL   J. Biol. Chem. 270:7773-7781(1995).
RN   [16]
RP   FUNCTION IN PROMOTING CHEMOTAXIS.
RX   PubMed=8760137; DOI=10.1152/ajplung.1996.271.1.l93;
RA   Osornio-Vargas A.R., Lindroos P.M., Coin P.G., Badgett A.,
RA   Hernandez-Rodriguez N.A., Bonner J.C.;
RT   "Maximal PDGF-induced lung fibroblast chemotaxis requires PDGF receptor-
RT   alpha.";
RL   Am. J. Physiol. 271:L93-L99(1996).
RN   [17]
RP   PHOSPHORYLATION AT TYR-768.
RX   PubMed=8617789; DOI=10.1074/jbc.271.9.5101;
RA   Yokote K., Mori S., Siegbahn A., Ronnstrand L., Wernstedt C., Heldin C.H.,
RA   Claesson-Welsh L.;
RT   "Structural determinants in the platelet-derived growth factor alpha-
RT   receptor implicated in modulation of chemotaxis.";
RL   J. Biol. Chem. 271:5101-5111(1996).
RN   [18]
RP   INTERACTION WITH GRB7 AND PIK3R1.
RX   PubMed=8940081; DOI=10.1074/jbc.271.48.30942;
RA   Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.;
RT   "Grb7 is a downstream signaling component of platelet-derived growth factor
RT   alpha- and beta-receptors.";
RL   J. Biol. Chem. 271:30942-30949(1996).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF PTPN11; ACTIVATION OF HRAS AND REGULATION OF
RP   CELL PROLIFERATION, PHOSPHORYLATION AT TYR-720, INTERACTION WITH GRB2;
RP   PTPN11; PLCG1 AND PIK3R1, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF TYR-720.
RX   PubMed=8943348; DOI=10.1128/mcb.16.12.6926;
RA   Bazenet C.E., Gelderloos J.A., Kazlauskas A.;
RT   "Phosphorylation of tyrosine 720 in the platelet-derived growth factor
RT   alpha receptor is required for binding of Grb2 and SHP-2 but not for
RT   activation of Ras or cell proliferation.";
RL   Mol. Cell. Biol. 16:6926-6936(1996).
RN   [20]
RP   INTERACTION WITH CRK, PHOSPHORYLATION AT TYR-762, AND MUTAGENESIS OF
RP   TYR-762.
RX   PubMed=10733900; DOI=10.1006/bbrc.2000.2374;
RA   Matsumoto T., Yokote K., Take A., Takemoto M., Asaumi S., Hashimoto Y.,
RA   Matsuda M., Saito Y., Mori S.;
RT   "Differential interaction of CrkII adaptor protein with platelet-derived
RT   growth factor alpha- and beta-receptors is determined by its internal
RT   tyrosine phosphorylation.";
RL   Biochem. Biophys. Res. Commun. 270:28-33(2000).
RN   [21]
RP   INTERACTION WITH SHF, AND PHOSPHORYLATION AT TYR-720.
RX   PubMed=11095946; DOI=10.1006/bbrc.2000.3847;
RA   Lindholm C.K., Frantz J.D., Shoelson S.E., Welsh M.;
RT   "Shf, a Shb-like adapter protein, is involved in PDGF-alpha-receptor
RT   regulation of apoptosis.";
RL   Biochem. Biophys. Res. Commun. 278:537-543(2000).
RN   [22]
RP   FUNCTION IN PLATELET ACTIVATION.
RX   PubMed=10947961; DOI=10.1042/bj3500469;
RA   Selheim F., Fukami M.H., Holmsen H., Vassbotn F.S.;
RT   "Platelet-derived-growth-factor-induced signalling in human platelets:
RT   phosphoinositide-3-kinase-dependent inhibition of platelet activation.";
RL   Biochem. J. 350:469-475(2000).
RN   [23]
RP   FUNCTION IN ACTIVATION OF MAPK1/ERK2 AND/OR MAPK3/ERK1, DEGRADATION,
RP   PHOSPHORYLATION AT TYR-572 AND TYR-574, AND MUTAGENESIS OF TYR-572 AND
RP   TYR-574.
RX   PubMed=10734113; DOI=10.1074/jbc.275.13.9620;
RA   Rosenkranz S., Ikuno Y., Leong F.L., Klinghoffer R.A., Miyake S., Band H.,
RA   Kazlauskas A.;
RT   "Src family kinases negatively regulate platelet-derived growth factor
RT   alpha receptor-dependent signaling and disease progression.";
RL   J. Biol. Chem. 275:9620-9627(2000).
RN   [24]
RP   FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC.
RX   PubMed=11297552; DOI=10.1074/jbc.m101056200;
RA   Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O.,
RA   Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M.,
RA   Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.;
RT   "Platelet-derived growth factor C (PDGF-C), a novel growth factor that
RT   binds to PDGF alpha and beta receptor.";
RL   J. Biol. Chem. 276:27406-27414(2001).
RN   [25]
RP   SUBCELLULAR LOCATION, INTERACTION WITH SRC, AND MUTAGENESIS OF TYR-572 AND
RP   TYR-574.
RX   PubMed=14644164; DOI=10.1016/j.yexcr.2003.08.001;
RA   Avrov K., Kazlauskas A.;
RT   "The role of c-Src in platelet-derived growth factor alpha receptor
RT   internalization.";
RL   Exp. Cell Res. 291:426-434(2003).
RN   [26]
RP   INVOLVEMENT IN HES.
RX   PubMed=12660384; DOI=10.1056/nejmoa025217;
RA   Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J.,
RA   Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A.,
RA   Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P.,
RA   Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P.,
RA   Coutre S.E., Stone R., Gilliland D.G.;
RT   "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a
RT   therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.";
RL   N. Engl. J. Med. 348:1201-1214(2003).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1; MAP KINASES; STAT1 AND STAT3,
RP   INVOLVEMENT IN GIST, VARIANTS ASP-561; VAL-842; 842-ASP--HIS-845 DEL AND
RP   845-HIS--PRO-448 DEL, AND CHARACTERIZATION OF VARIANTS ASP-561; VAL-842;
RP   842-ASP--HIS-845 DEL AND 845-HIS--PRO-448 DEL.
RX   PubMed=12522257; DOI=10.1126/science.1079666;
RA   Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J.,
RA   Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D.,
RA   Fletcher C.D., Fletcher J.A.;
RT   "PDGFRA activating mutations in gastrointestinal stromal tumors.";
RL   Science 299:708-710(2003).
RN   [28]
RP   INVOLVEMENT IN GIST, VARIANTS ASP-561; LYS-659; TYR-842; VAL-842;
RP   842-ASP--HIS-845 DEL 845-HIS--PRO-448 DEL AND CYS-849, CHARACTERIZATION OF
RP   VARIANTS ASP-561; LYS-659; TYR-842; VAL-842; 842-ASP--HIS-845 DEL
RP   845-HIS--PRO-448 DEL AND CYS-849, AND ACTIVITY REGULATION.
RX   PubMed=15928335; DOI=10.1200/jco.2005.14.068;
RA   Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P.,
RA   Shiraga S., Bainbridge T., Morich J., Heinrich M.C.;
RT   "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum
RT   and in vitro sensitivity to imatinib.";
RL   J. Clin. Oncol. 23:5357-5364(2005).
RN   [29]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=17141222; DOI=10.1016/j.febslet.2006.11.034;
RA   Vantler M., Huntgeburth M., Caglayan E., Ten Freyhaus H., Schnabel P.,
RA   Rosenkranz S.;
RT   "PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha
RT   receptor is negatively regulated by Src family kinases.";
RL   FEBS Lett. 580:6769-6776(2006).
RN   [30]
RP   PHOSPHORYLATION AT TYR-754.
RX   PubMed=17604334; DOI=10.1158/1535-7163.mct-06-0720;
RA   Stock P., Monga D., Tan X., Micsenyi A., Loizos N., Monga S.P.;
RT   "Platelet-derived growth factor receptor-alpha: a novel therapeutic target
RT   in human hepatocellular cancer.";
RL   Mol. Cancer Ther. 6:1932-1941(2007).
RN   [31]
RP   INTERACTION WITH HHV-5 GB (MICROBIAL INFECTION).
RX   PubMed=20660204; DOI=10.1128/jvi.00710-10;
RA   Feire A.L., Roy R.M., Manley K., Compton T.;
RT   "The glycoprotein B disintegrin-like domain binds beta 1 integrin to
RT   mediate cytomegalovirus entry.";
RL   J. Virol. 84:10026-10037(2010).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF STAT 5A AND/OR STAT5B, ROLE IN
RP   HYPEREOSINOPHILIC SYNDROME, VARIANTS GLY-481; PRO-507; MET-562; ARG-570;
RP   GLN-650; SER-659; PRO-705; GLY-748 AND SER-849, CHARACTERIZATION OF
RP   VARIANTS GLY-481; PRO-507; MET-562; ARG-570; GLN-650; SER-659; PRO-705;
RP   GLY-748 AND SER-849, AND ACTIVITY REGULATION.
RX   PubMed=21224473; DOI=10.1182/blood-2010-05-286757;
RA   Elling C., Erben P., Walz C., Frickenhaus M., Schemionek M., Stehling M.,
RA   Serve H., Cross N.C., Hochhaus A., Hofmann W.K., Berdel W.E.,
RA   Muller-Tidow C., Reiter A., Koschmieder S.;
RT   "Novel imatinib-sensitive PDGFRA-activating point mutations in
RT   hypereosinophilic syndrome induce growth factor independence and leukemia-
RT   like disease.";
RL   Blood 117:2935-2943(2011).
RN   [33]
RP   FUNCTION IN CELL DIFFERENTIATION, AND UBIQUITINATION.
RX   PubMed=21596750; DOI=10.1074/jbc.m110.197525;
RA   Severe N., Miraoui H., Marie P.J.;
RT   "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic
RT   differentiation in human mesenchymal stromal cells in part by decreased
RT   Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast
RT   growth factor receptor 2 ubiquitination.";
RL   J. Biol. Chem. 286:24443-24450(2011).
RN   [34]
RP   ROLE IN DISEASE, CHARACTERIZATION OF VARIANT VAL-842, AND ACTIVITY
RP   REGULATION.
RX   PubMed=20972453; DOI=10.1038/onc.2010.476;
RA   von Bubnoff N., Gorantla S.P., Engh R.A., Oliveira T.M., Thone S.,
RA   Aberg E., Peschel C., Duyster J.;
RT   "The low frequency of clinical resistance to PDGFR inhibitors in myeloid
RT   neoplasms with abnormalities of PDGFRA might be related to the limited
RT   repertoire of possible PDGFRA kinase domain mutations in vitro.";
RL   Oncogene 30:933-943(2011).
RN   [35]
RP   REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION.
RX   PubMed=9739761; DOI=10.1016/s0304-419x(98)00015-8;
RA   Heldin C.H., Ostman A., Ronnstrand L.;
RT   "Signal transduction via platelet-derived growth factor receptors.";
RL   Biochim. Biophys. Acta 1378:F79-113(1998).
RN   [36]
RP   REVIEW ON ROLE IN DISEASE AND ACTIVITY REGULATION.
RX   PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002;
RA   Ostman A.;
RT   "PDGF receptors-mediators of autocrine tumor growth and regulators of tumor
RT   vasculature and stroma.";
RL   Cytokine Growth Factor Rev. 15:275-286(2004).
RN   [37]
RP   REVIEW ON ROLE IN DISEASE AND ACTIVITY REGULATION.
RX   PubMed=17419949; DOI=10.1016/s0065-230x(06)97011-0;
RA   Ostman A., Heldin C.H.;
RT   "PDGF receptors as targets in tumor treatment.";
RL   Adv. Cancer Res. 97:247-274(2007).
RN   [38]
RP   REVIEW ON FUNCTION IN DEVELOPMENT AND DISEASE; LIGANDS AND SIGNALING
RP   PATHWAYS.
RX   PubMed=18483217; DOI=10.1101/gad.1653708;
RA   Andrae J., Gallini R., Betsholtz C.;
RT   "Role of platelet-derived growth factors in physiology and medicine.";
RL   Genes Dev. 22:1276-1312(2008).
RN   [39]
RP   INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEINS GH; GL AND GO (MICROBIAL
RP   INFECTION).
RX   PubMed=28403202; DOI=10.1371/journal.ppat.1006281;
RA   Wu Y., Prager A., Boos S., Resch M., Brizic I., Mach M., Wildner S.,
RA   Scrivano L., Adler B.;
RT   "Human cytomegalovirus glycoprotein complex gH/gL/gO uses PDGFR-alpha as a
RT   key for entry.";
RL   PLoS Pathog. 13:E1006281-E1006281(2017).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1185-1189 IN COMPLEX WITH SLC9A3R1
RP   AND PDGFRB.
RX   PubMed=11882663; DOI=10.1074/jbc.m201507200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural determinants of the Na+/H+ exchanger regulatory factor
RT   interaction with the beta 2 adrenergic and platelet-derived growth factor
RT   receptors.";
RL   J. Biol. Chem. 277:18973-18978(2002).
RN   [41]
RP   INVOLVEMENT IN GISTPS, AND VARIANT GISTPS TYR-846.
RX   PubMed=14699510; DOI=10.1053/j.gastro.2003.10.079;
RA   Chompret A., Kannengiesser C., Barrois M., Terrier P., Dahan P., Tursz T.,
RA   Lenoir G.M., Bressac-De Paillerets B.;
RT   "PDGFRA germline mutation in a family with multiple cases of
RT   gastrointestinal stromal tumor.";
RL   Gastroenterology 126:318-321(2004).
RN   [42]
RP   VARIANT GISTPS CYS-555, CHARACTERIZATION OF VARIANT GISTPS CYS-555, AND
RP   FUNCTION.
RX   PubMed=17087943; DOI=10.1053/j.gastro.2006.07.002;
RA   de Raedt T., Cools J., Debiec-Rychter M., Brems H., Mentens N., Sciot R.,
RA   Himpens J., de Wever I., Schoeffski P., Marynen P., Legius E.;
RT   "Intestinal neurofibromatosis is a subtype of familial GIST and results
RT   from a dominant activating mutation in PDGFRA.";
RL   Gastroenterology 131:1907-1912(2006).
RN   [43]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-79; ASP-426; PRO-478; CYS-764; ARG-829;
RP   LYS-996 AND ASN-1071.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [44]
RP   VARIANT GISTPS LEU-653.
RX   PubMed=25975287; DOI=10.1038/modpathol.2015.56;
RA   Ricci R., Martini M., Cenci T., Carbone A., Lanza P., Biondi A., Rindi G.,
RA   Cassano A., Larghi A., Persiani R., Larocca L.M.;
RT   "PDGFRA-mutant syndrome.";
RL   Mod. Pathol. 28:954-964(2015).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor
CC       for PDGFA, PDGFB and PDGFC and plays an essential role in the
CC       regulation of embryonic development, cell proliferation, survival and
CC       chemotaxis. Depending on the context, promotes or inhibits cell
CC       proliferation and cell migration. Plays an important role in the
CC       differentiation of bone marrow-derived mesenchymal stem cells. Required
CC       for normal skeleton development and cephalic closure during embryonic
CC       development. Required for normal development of the mucosa lining the
CC       gastrointestinal tract, and for recruitment of mesenchymal cells and
CC       normal development of intestinal villi. Plays a role in cell migration
CC       and chemotaxis in wound healing. Plays a role in platelet activation,
CC       secretion of agonists from platelet granules, and in thrombin-induced
CC       platelet aggregation. Binding of its cognate ligands - homodimeric
CC       PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or
CC       homodimeric PDGFC -leads to the activation of several signaling
CC       cascades; the response depends on the nature of the bound ligand and is
CC       modulated by the formation of heterodimers between PDGFRA and PDGFRB.
CC       Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to
CC       the production of the cellular signaling molecules diacylglycerol and
CC       inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the
CC       activation of protein kinase C. Phosphorylates PIK3R1, the regulatory
CC       subunit of phosphatidylinositol 3-kinase, and thereby mediates
CC       activation of the AKT1 signaling pathway. Mediates activation of HRAS
CC       and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes
CC       activation of STAT family members STAT1, STAT3 and STAT5A and/or
CC       STAT5B. Receptor signaling is down-regulated by protein phosphatases
CC       that dephosphorylate the receptor and its down-stream effectors, and by
CC       rapid internalization of the activated receptor.
CC       {ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:10947961,
CC       ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:12522257,
CC       ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:17087943,
CC       ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17141222,
CC       ECO:0000269|PubMed:20972453, ECO:0000269|PubMed:21224473,
CC       ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:2554309,
CC       ECO:0000269|PubMed:8188664, ECO:0000269|PubMed:8760137,
CC       ECO:0000269|PubMed:8943348}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. Binding of PDGFA and/or PDGFB leads to dimerization
CC       and activation by autophosphorylation on tyrosine residues. Inhibited
CC       by imatinib, nilotinib and sorafenib. {ECO:0000269|PubMed:15928335,
CC       ECO:0000269|PubMed:20972453, ECO:0000269|PubMed:21224473}.
CC   -!- SUBUNIT: Interacts with homodimeric PDGFA, PDGFB and PDGFC, and with
CC       heterodimers formed by PDGFA and PDGFB. Monomer in the absence of bound
CC       ligand. Interaction with dimeric PDGFA, PDGFB and/or PDGFC leads to
CC       receptor dimerization, where both PDGFRA homodimers and heterodimers
CC       with PDGFRB are observed. Interacts (tyrosine phosphorylated) with SHB
CC       (via SH2 domain) (By similarity). Interacts (tyrosine phosphorylated)
CC       with SHF (via SH2 domain). Interacts (tyrosine phosphorylated) with SRC
CC       (via SH2 domain). Interacts (tyrosine phosphorylated) with PIK3R1.
CC       Interacts (tyrosine phosphorylated) with PLCG1 (via SH2 domain).
CC       Interacts (tyrosine phosphorylated) with CRK, GRB2 and GRB7.
CC       {ECO:0000250, ECO:0000269|PubMed:10733900, ECO:0000269|PubMed:11095946,
CC       ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11882663,
CC       ECO:0000269|PubMed:14644164, ECO:0000269|PubMed:1646396,
CC       ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2173144,
CC       ECO:0000269|PubMed:2536956, ECO:0000269|PubMed:2544881,
CC       ECO:0000269|PubMed:7535778, ECO:0000269|PubMed:7679113,
CC       ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:8943348}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human
CC       cytomegalovirus/HHV-5 envelope glycoprotein B/gB. Interacts also with
CC       the trimeric complex gH-gL-gO. {ECO:0000269|PubMed:20660204,
CC       ECO:0000269|PubMed:28403202}.
CC   -!- INTERACTION:
CC       P16234; P46108: CRK; NbExp=4; IntAct=EBI-2861522, EBI-886;
CC       P16234; P46109: CRKL; NbExp=3; IntAct=EBI-2861522, EBI-910;
CC       P16234; P00533: EGFR; NbExp=4; IntAct=EBI-2861522, EBI-297353;
CC       P16234; Q8N6L0: KASH5; NbExp=3; IntAct=EBI-2861522, EBI-749265;
CC       P16234; P04085: PDGFA; NbExp=6; IntAct=EBI-2861522, EBI-2881386;
CC       P16234; P01127: PDGFB; NbExp=11; IntAct=EBI-2861522, EBI-1554925;
CC       P16234; Q9NRA1: PDGFC; NbExp=3; IntAct=EBI-2861522, EBI-8833587;
CC       P16234-1; Q9NRA1-1: PDGFC; NbExp=2; IntAct=EBI-15499330, EBI-15499301;
CC       P16234-1; A8T7D5: UL55; Xeno; NbExp=2; IntAct=EBI-15499330, EBI-15722055;
CC       P16234-2; P05067: APP; NbExp=3; IntAct=EBI-13380852, EBI-77613;
CC       P16234-2; Q8IY26: PLPP6; NbExp=3; IntAct=EBI-13380852, EBI-11721828;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664}. Cell
CC       projection, cilium {ECO:0000250|UniProtKB:P26618}. Golgi apparatus
CC       {ECO:0000250|UniProtKB:P26618}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P16234-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P16234-2; Sequence=VSP_007833, VSP_007834;
CC       Name=3;
CC         IsoId=P16234-3; Sequence=VSP_042015, VSP_042016;
CC   -!- TISSUE SPECIFICITY: Detected in platelets (at protein level). Widely
CC       expressed. Detected in brain, fibroblasts, smooth muscle, heart, and
CC       embryo. Expressed in primary and metastatic colon tumors and in normal
CC       colon tissue. {ECO:0000269|PubMed:2536956, ECO:0000269|PubMed:7896447,
CC       ECO:0000269|PubMed:8188664}.
CC   -!- PTM: N-glycosylated.
CC   -!- PTM: Ubiquitinated, leading to its internalization and degradation.
CC       {ECO:0000305|PubMed:21596750}.
CC   -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding.
CC       Autophosphorylation occurs in trans, i.e. one subunit of the dimeric
CC       receptor phosphorylates tyrosine residues on the other subunit.
CC       Phosphorylation at Tyr-731 and Tyr-742 is important for interaction
CC       with PIK3R1. Phosphorylation at Tyr-720 and Tyr-754 is important for
CC       interaction with PTPN11. Phosphorylation at Tyr-762 is important for
CC       interaction with CRK. Phosphorylation at Tyr-572 and Tyr-574 is
CC       important for interaction with SRC and SRC family members.
CC       Phosphorylation at Tyr-988 and Tyr-1018 is important for interaction
CC       with PLCG1. {ECO:0000269|PubMed:10733900, ECO:0000269|PubMed:10734113,
CC       ECO:0000269|PubMed:11095946, ECO:0000269|PubMed:1646396,
CC       ECO:0000269|PubMed:7535778, ECO:0000269|PubMed:8943348}.
CC   -!- DISEASE: Note=A chromosomal aberration involving PDGFRA is found in
CC       some cases of hypereosinophilic syndrome. Interstitial chromosomal
CC       deletion del(4)(q12q12) causes the fusion of FIP1L1 and PDGFRA (FIP1L1-
CC       PDGFRA). Mutations that cause overexpression and/or constitutive
CC       activation of PDGFRA may be a cause of hypereosinophilic syndrome.
CC       {ECO:0000269|PubMed:12808148}.
CC   -!- DISEASE: Gastrointestinal stromal tumor (GIST) [MIM:606764]: Common
CC       mesenchymal neoplasms arising in the gastrointestinal tract, most often
CC       in the stomach. They are histologically, immunohistochemically, and
CC       genetically different from typical leiomyomas, leiomyosarcomas, and
CC       schwannomas. Most GISTs are composed of a fairly uniform population of
CC       spindle-shaped cells. Some tumors are dominated by epithelioid cells or
CC       contain a mixture of spindle and epithelioid morphologies. Primary
CC       GISTs in the gastrointestinal tract commonly metastasize in the omentum
CC       and mesenteries, often as multiple nodules. However, primary tumors may
CC       also occur outside of the gastrointestinal tract, in other intra-
CC       abdominal locations, especially in the omentum and mesentery.
CC       {ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:15928335}. Note=The
CC       gene represented in this entry may be involved in disease pathogenesis.
CC       Mutations causing PDGFRA constitutive activation have been found in
CC       gastrointestinal stromal tumors lacking KIT mutations
CC       (PubMed:12522257). {ECO:0000269|PubMed:12522257}.
CC   -!- DISEASE: GIST-plus syndrome (GISTPS) [MIM:175510]: A disorder
CC       characterized by multiple mesenchymal tumors of the gastrointestinal
CC       tract, including gastrointestinal stromal tumor, inflammatory fibroid
CC       polyps, and fibroid tumors. Additional features are coarse facies and
CC       skin, broad hands and feet, and premature tooth loss. GISTPS is an
CC       autosomal dominant disease with incomplete penetrance. Gastrointestinal
CC       stromal tumor and inflammatory fibroid polyps may also occur in
CC       isolation. {ECO:0000269|PubMed:14699510, ECO:0000269|PubMed:17087943,
CC       ECO:0000269|PubMed:25975287}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP69563.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M22734; AAA60048.1; -; mRNA.
DR   EMBL; M21574; AAA96715.1; -; mRNA.
DR   EMBL; D50017; BAA08742.1; -; Genomic_DNA.
DR   EMBL; AK316578; BAG38166.1; -; mRNA.
DR   EMBL; AC098587; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC138779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015186; AAH15186.1; -; mRNA.
DR   EMBL; BC063414; AAH63414.1; -; mRNA.
DR   EMBL; AY229892; AAP69563.1; ALT_INIT; mRNA.
DR   CCDS; CCDS3495.1; -. [P16234-1]
DR   PIR; A40162; PFHUGA.
DR   RefSeq; NP_001334758.1; NM_001347829.1. [P16234-1]
DR   RefSeq; NP_006197.1; NM_006206.5. [P16234-1]
DR   RefSeq; XP_005265800.1; XM_005265743.1. [P16234-1]
DR   PDB; 1GQ5; X-ray; 2.20 A; -.
DR   PDB; 5GRN; X-ray; 1.77 A; A=550-973.
DR   PDB; 5K5X; X-ray; 2.17 A; A=550-973.
DR   PDB; 6A32; X-ray; 1.87 A; A=550-973.
DR   PDB; 6JOI; X-ray; 3.10 A; A=550-973.
DR   PDB; 6JOJ; X-ray; 2.60 A; A=550-973.
DR   PDB; 6JOK; X-ray; 3.80 A; A=550-973.
DR   PDB; 6JOL; X-ray; 1.90 A; A=550-973.
DR   PDB; 7LBF; EM; 2.80 A; D=1-524.
DR   PDBsum; 1GQ5; -.
DR   PDBsum; 5GRN; -.
DR   PDBsum; 5K5X; -.
DR   PDBsum; 6A32; -.
DR   PDBsum; 6JOI; -.
DR   PDBsum; 6JOJ; -.
DR   PDBsum; 6JOK; -.
DR   PDBsum; 6JOL; -.
DR   PDBsum; 7LBF; -.
DR   AlphaFoldDB; P16234; -.
DR   SMR; P16234; -.
DR   BioGRID; 111182; 324.
DR   ComplexPortal; CPX-2881; PDGF receptor alpha - PDGF-AA complex.
DR   ComplexPortal; CPX-2883; PDGF receptor alpha-beta - PDGF-BB complex.
DR   ComplexPortal; CPX-2884; PDGF receptor alpha - PDGF-BB complex.
DR   ComplexPortal; CPX-2885; PDGF receptor alpha - PDGF-AB complex.
DR   ComplexPortal; CPX-2887; PDGF receptor alpha - PDGF-CC complex.
DR   ComplexPortal; CPX-2888; PDGF receptor alpha-beta - PDGF-CC complex.
DR   ComplexPortal; CPX-2890; PDGF receptor alpha-beta - PDGF-DD complex.
DR   ComplexPortal; CPX-2892; PDGF receptor alpha-beta - PDGF-AB complex.
DR   CORUM; P16234; -.
DR   DIP; DIP-5736N; -.
DR   IntAct; P16234; 123.
DR   MINT; P16234; -.
DR   STRING; 9606.ENSP00000257290; -.
DR   BindingDB; P16234; -.
DR   ChEMBL; CHEMBL2007; -.
DR   DrugBank; DB12742; Amuvatinib.
DR   DrugBank; DB00102; Becaplermin.
DR   DrugBank; DB12147; Erdafitinib.
DR   DrugBank; DB10772; Foreskin keratinocyte (neonatal).
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB06595; Midostaurin.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB06043; Olaratumab.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB14840; Ripretinib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugBank; DB05146; XL820.
DR   DrugCentral; P16234; -.
DR   GuidetoPHARMACOLOGY; 1803; -.
DR   GlyGen; P16234; 8 sites.
DR   iPTMnet; P16234; -.
DR   PhosphoSitePlus; P16234; -.
DR   BioMuta; PDGFRA; -.
DR   DMDM; 129892; -.
DR   CPTAC; CPTAC-1767; -.
DR   jPOST; P16234; -.
DR   MassIVE; P16234; -.
DR   MaxQB; P16234; -.
DR   PaxDb; P16234; -.
DR   PeptideAtlas; P16234; -.
DR   PRIDE; P16234; -.
DR   ProteomicsDB; 53328; -. [P16234-1]
DR   ProteomicsDB; 53329; -. [P16234-2]
DR   ProteomicsDB; 53330; -. [P16234-3]
DR   ABCD; P16234; 32 sequenced antibodies.
DR   Antibodypedia; 1381; 2277 antibodies from 45 providers.
DR   DNASU; 5156; -.
DR   Ensembl; ENST00000257290.10; ENSP00000257290.5; ENSG00000134853.12. [P16234-1]
DR   Ensembl; ENST00000508170.5; ENSP00000425648.1; ENSG00000134853.12. [P16234-2]
DR   Ensembl; ENST00000509490.5; ENSP00000424218.1; ENSG00000134853.12. [P16234-3]
DR   GeneID; 5156; -.
DR   KEGG; hsa:5156; -.
DR   MANE-Select; ENST00000257290.10; ENSP00000257290.5; NM_006206.6; NP_006197.1.
DR   UCSC; uc003hal.4; human. [P16234-1]
DR   CTD; 5156; -.
DR   DisGeNET; 5156; -.
DR   GeneCards; PDGFRA; -.
DR   HGNC; HGNC:8803; PDGFRA.
DR   HPA; ENSG00000134853; Tissue enhanced (ovary).
DR   MalaCards; PDGFRA; -.
DR   MIM; 173490; gene.
DR   MIM; 175510; phenotype.
DR   MIM; 606764; phenotype.
DR   MIM; 607685; phenotype.
DR   neXtProt; NX_P16234; -.
DR   OpenTargets; ENSG00000134853; -.
DR   Orphanet; 585877; B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality.
DR   Orphanet; 168940; Chronic eosinophilic leukemia.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 168947; Myeloid/lymphoid neoplasm associated with PDGFRA rearrangement.
DR   Orphanet; 314950; Primary hypereosinophilic syndrome.
DR   PharmGKB; PA33147; -.
DR   VEuPathDB; HostDB:ENSG00000134853; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000156021; -.
DR   HOGENOM; CLU_000288_49_0_1; -.
DR   InParanoid; P16234; -.
DR   OMA; CFLTGPF; -.
DR   OrthoDB; 236292at2759; -.
DR   PhylomeDB; P16234; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P16234; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-186797; Signaling by PDGF.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants.
DR   Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants.
DR   Reactome; R-HSA-9674396; Imatinib-resistant PDGFR mutants.
DR   Reactome; R-HSA-9674401; Sunitinib-resistant PDGFR mutants.
DR   Reactome; R-HSA-9674403; Regorafenib-resistant PDGFR mutants.
DR   Reactome; R-HSA-9674404; Sorafenib-resistant PDGFR mutants.
DR   Reactome; R-HSA-9674428; PDGFR mutants bind TKIs.
DR   SignaLink; P16234; -.
DR   SIGNOR; P16234; -.
DR   BioGRID-ORCS; 5156; 37 hits in 1100 CRISPR screens.
DR   ChiTaRS; PDGFRA; human.
DR   EvolutionaryTrace; P16234; -.
DR   GeneWiki; PDGFRA; -.
DR   GenomeRNAi; 5156; -.
DR   Pharos; P16234; Tclin.
DR   PRO; PR:P16234; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P16234; protein.
DR   Bgee; ENSG00000134853; Expressed in tibia and 205 other tissues.
DR   ExpressionAtlas; P16234; baseline and differential.
DR   Genevisible; P16234; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005929; C:cilium; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005902; C:microvillus; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0062063; F:BBSome binding; IEA:Ensembl.
DR   GO; GO:0019838; F:growth factor binding; IBA:GO_Central.
DR   GO; GO:0005018; F:platelet-derived growth factor alpha-receptor activity; IDA:UniProtKB.
DR   GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor activity; IDA:BHF-UCL.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB.
DR   GO; GO:0001775; P:cell activation; TAS:BHF-UCL.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:MGI.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048704; P:embryonic skeletal system morphogenesis; ISS:UniProtKB.
DR   GO; GO:0008210; P:estrogen metabolic process; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0060325; P:face morphogenesis; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0033327; P:Leydig cell differentiation; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0001553; P:luteinization; ISS:UniProtKB.
DR   GO; GO:0030539; P:male genitalia development; IEA:Ensembl.
DR   GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB.
DR   GO; GO:0010544; P:negative regulation of platelet activation; IDA:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IMP:UniProtKB.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035790; P:platelet-derived growth factor receptor-alpha signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:BHF-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0050920; P:regulation of chemotaxis; IMP:UniProtKB.
DR   GO; GO:2000739; P:regulation of mesenchymal stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB.
DR   GO; GO:0060021; P:roof of mouth development; IEA:Ensembl.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0050872; P:white fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR027290; PDGFRA.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PIRSF; PIRSF500950; Alpha-PDGF_receptor; 1.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Cell projection; Chemotaxis; Developmental protein; Disease variant;
KW   Disulfide bond; Glycoprotein; Golgi apparatus; Host-virus interaction;
KW   Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..23
FT   CHAIN           24..1089
FT                   /note="Platelet-derived growth factor receptor alpha"
FT                   /id="PRO_0000016760"
FT   TOPO_DOM        24..528
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        529..549
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        550..1089
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          24..113
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          117..201
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          202..306
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          319..410
FT                   /note="Ig-like C2-type 4"
FT   DOMAIN          414..517
FT                   /note="Ig-like C2-type 5"
FT   DOMAIN          593..954
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1018..1089
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1029..1044
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1045..1060
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        818
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         599..607
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         627
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            578..579
FT                   /note="Breakpoint for interstitial deletion to form the
FT                   FIP1L1-PDGFRA fusion protein"
FT   MOD_RES         572
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10734113"
FT   MOD_RES         574
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10734113"
FT   MOD_RES         720
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11095946,
FT                   ECO:0000269|PubMed:8943348"
FT   MOD_RES         731
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:1646396"
FT   MOD_RES         742
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:1646396"
FT   MOD_RES         754
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17604334"
FT   MOD_RES         762
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10733900"
FT   MOD_RES         768
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8617789"
FT   MOD_RES         849
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         988
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:7535778"
FT   MOD_RES         1018
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:7535778"
FT   CARBOHYD        42
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        76
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        103
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        179
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        353
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        359
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        458
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        468
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        49..100
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        150..189
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        235..290
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        435..501
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         210..218
FT                   /note="ATSELDLEM -> GTCIISFLL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_007833"
FT   VAR_SEQ         219..1089
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_007834"
FT   VAR_SEQ         720..743
FT                   /note="YVILSFENNGDYMDMKQADTTQYV -> SGQGCLSSGTLQELSVDLQARGPC
FT                   (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042015"
FT   VAR_SEQ         744..1089
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042016"
FT   VARIANT         79
FT                   /note="G -> D (in dbSNP:rs36035373)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042032"
FT   VARIANT         426
FT                   /note="G -> D (in dbSNP:rs55865821)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042033"
FT   VARIANT         478
FT                   /note="S -> P (in dbSNP:rs35597368)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_034378"
FT   VARIANT         481
FT                   /note="R -> G (in a hypereosinophilic syndrome sample; does
FT                   not lead to constitutive kinase activation)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066460"
FT   VARIANT         507
FT                   /note="L -> P (in a hypereosinophilic syndrome sample; does
FT                   not lead to constitutive kinase activation)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066461"
FT   VARIANT         555
FT                   /note="Y -> C (in GISTPS; increased platelet-derived growth
FT                   factor alpha-receptor activity; constitutively activated
FT                   kinase; dbSNP:rs121908589)"
FT                   /evidence="ECO:0000269|PubMed:17087943"
FT                   /id="VAR_083158"
FT   VARIANT         561
FT                   /note="V -> D (in a GIST sample; constitutively activated
FT                   kinase; dbSNP:rs121908586)"
FT                   /evidence="ECO:0000269|PubMed:12522257,
FT                   ECO:0000269|PubMed:15928335"
FT                   /id="VAR_066462"
FT   VARIANT         562
FT                   /note="I -> M (in a hypereosinophilic syndrome sample; does
FT                   not lead to constitutive kinase activation)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066463"
FT   VARIANT         570
FT                   /note="H -> R (in a hypereosinophilic syndrome sample; does
FT                   not lead to constitutive kinase activation)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066464"
FT   VARIANT         650
FT                   /note="H -> Q (in a hypereosinophilic syndrome sample;
FT                   constitutively activated kinase)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066465"
FT   VARIANT         653
FT                   /note="P -> L (in GISTPS; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:25975287"
FT                   /id="VAR_083159"
FT   VARIANT         659
FT                   /note="N -> K (in GIST sample; constitutively activated
FT                   kinase; dbSNP:rs1057519700)"
FT                   /evidence="ECO:0000269|PubMed:15928335"
FT                   /id="VAR_066466"
FT   VARIANT         659
FT                   /note="N -> S (in a hypereosinophilic syndrome sample;
FT                   constitutively activated kinase)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066467"
FT   VARIANT         705
FT                   /note="L -> P (in a hypereosinophilic syndrome sample; does
FT                   not lead to constitutive kinase activation)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066468"
FT   VARIANT         748
FT                   /note="R -> G (in a hypereosinophilic syndrome sample;
FT                   constitutively activated kinase)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066469"
FT   VARIANT         764
FT                   /note="R -> C (in dbSNP:rs34392012)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042034"
FT   VARIANT         829
FT                   /note="G -> R (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042035"
FT   VARIANT         842..845
FT                   /note="Missing (in a GIST sample; constitutively activated
FT                   kinase)"
FT                   /evidence="ECO:0000269|PubMed:12522257,
FT                   ECO:0000269|PubMed:15928335"
FT                   /id="VAR_066470"
FT   VARIANT         842
FT                   /note="D -> V (in a GIST sample; imatinib resistant,
FT                   constitutively activated kinase; dbSNP:rs121908585)"
FT                   /evidence="ECO:0000269|PubMed:12522257,
FT                   ECO:0000269|PubMed:15928335, ECO:0000269|PubMed:20972453"
FT                   /id="VAR_066471"
FT   VARIANT         842
FT                   /note="D -> Y (in a GIST sample; imatinib sensitive,
FT                   constitutively activated kinase; dbSNP:rs121913265)"
FT                   /evidence="ECO:0000269|PubMed:15928335"
FT                   /id="VAR_066472"
FT   VARIANT         845..848
FT                   /note="Missing (in a GIST sample; constitutively activated
FT                   kinase)"
FT                   /evidence="ECO:0000269|PubMed:12522257,
FT                   ECO:0000269|PubMed:15928335"
FT                   /id="VAR_066473"
FT   VARIANT         846
FT                   /note="D -> Y (in GISTPS; unknown pathological
FT                   significance; dbSNP:rs121908588)"
FT                   /evidence="ECO:0000269|PubMed:14699510"
FT                   /id="VAR_083160"
FT   VARIANT         849
FT                   /note="Y -> C (in GIST)"
FT                   /evidence="ECO:0000269|PubMed:15928335"
FT                   /id="VAR_066474"
FT   VARIANT         849
FT                   /note="Y -> S (in a hypereosinophilic syndrome sample;
FT                   constitutively activated kinase)"
FT                   /evidence="ECO:0000269|PubMed:21224473"
FT                   /id="VAR_066475"
FT   VARIANT         996
FT                   /note="E -> K (in a metastatic melanoma sample; somatic
FT                   mutation; dbSNP:rs779173667)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042036"
FT   VARIANT         1071
FT                   /note="D -> N (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation; dbSNP:rs376544204)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042037"
FT   MUTAGEN         572
FT                   /note="Y->F: Abolishes interaction with SRC-family members
FT                   and impairs internalization of the activated receptor; when
FT                   associated with F-574."
FT                   /evidence="ECO:0000269|PubMed:10734113,
FT                   ECO:0000269|PubMed:14644164"
FT   MUTAGEN         574
FT                   /note="Y->F: Abolishes interaction with SRC-family members
FT                   and impairs internalization of the activated receptor; when
FT                   associated with F-572."
FT                   /evidence="ECO:0000269|PubMed:10734113,
FT                   ECO:0000269|PubMed:14644164"
FT   MUTAGEN         720
FT                   /note="Y->F: Strongly reduced interaction with PTPN11 and
FT                   GRB2."
FT                   /evidence="ECO:0000269|PubMed:8943348"
FT   MUTAGEN         731
FT                   /note="Y->F: No effect on autophosphorylation and
FT                   phosphorylation of PLCG1. Abolishes activation of
FT                   phosphatidylinositol 3-kinase."
FT                   /evidence="ECO:0000269|PubMed:1646396"
FT   MUTAGEN         742
FT                   /note="Y->F: No effect on autophosphorylation and
FT                   phosphorylation of PLCG1. Abolishes activation of
FT                   phosphatidylinositol 3-kinase."
FT                   /evidence="ECO:0000269|PubMed:1646396"
FT   MUTAGEN         762
FT                   /note="Y->F: Abolishes interaction with CRK."
FT                   /evidence="ECO:0000269|PubMed:10733900"
FT   STRAND          29..32
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          35..38
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          41..43
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          46..53
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          55..58
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          70..72
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          80..86
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   HELIX           92..94
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          96..102
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   HELIX           103..105
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          107..111
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          114..120
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          133..141
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          144..148
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          152..156
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          159..167
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   TURN            174..176
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          177..181
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          184..192
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          197..199
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          203..208
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          216..219
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          224..226
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          231..237
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          239..241
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          246..248
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   HELIX           252..254
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          258..264
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          266..268
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          270..279
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          286..292
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          301..306
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          308..310
FT                   /evidence="ECO:0007829|PDB:7LBF"
FT   STRAND          560..565
FT                   /evidence="ECO:0007829|PDB:6A32"
FT   STRAND          567..570
FT                   /evidence="ECO:0007829|PDB:6A32"
FT   STRAND          572..574
FT                   /evidence="ECO:0007829|PDB:6A32"
FT   HELIX           577..579
FT                   /evidence="ECO:0007829|PDB:6A32"
FT   HELIX           584..586
FT                   /evidence="ECO:0007829|PDB:6JOL"
FT   HELIX           590..592
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          593..601
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          603..614
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          616..618
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          620..629
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           635..651
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          660..664
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          666..669
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          671..675
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          678..681
FT                   /evidence="ECO:0007829|PDB:6JOJ"
FT   HELIX           682..688
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           690..696
FT                   /evidence="ECO:0007829|PDB:6A32"
FT   HELIX           769..774
FT                   /evidence="ECO:0007829|PDB:6A32"
FT   HELIX           778..781
FT                   /evidence="ECO:0007829|PDB:5K5X"
FT   HELIX           792..811
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           821..823
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          824..827
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   TURN            828..830
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          831..834
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           838..840
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           843..845
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          849..851
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   STRAND          853..857
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           859..861
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           864..869
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           874..889
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           903..910
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           923..932
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           937..939
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           943..953
FT                   /evidence="ECO:0007829|PDB:5GRN"
FT   HELIX           956..971
FT                   /evidence="ECO:0007829|PDB:6A32"
SQ   SEQUENCE   1089 AA;  122670 MW;  5E3FB9940ACD1BE8 CRC64;
     MGTSHPAFLV LGCLLTGLSL ILCQLSLPSI LPNENEKVVQ LNSSFSLRCF GESEVSWQYP
     MSEEESSDVE IRNEENNSGL FVTVLEVSSA SAAHTGLYTC YYNHTQTEEN ELEGRHIYIY
     VPDPDVAFVP LGMTDYLVIV EDDDSAIIPC RTTDPETPVT LHNSEGVVPA SYDSRQGFNG
     TFTVGPYICE ATVKGKKFQT IPFNVYALKA TSELDLEMEA LKTVYKSGET IVVTCAVFNN
     EVVDLQWTYP GEVKGKGITM LEEIKVPSIK LVYTLTVPEA TVKDSGDYEC AARQATREVK
     EMKKVTISVH EKGFIEIKPT FSQLEAVNLH EVKHFVVEVR AYPPPRISWL KNNLTLIENL
     TEITTDVEKI QEIRYRSKLK LIRAKEEDSG HYTIVAQNED AVKSYTFELL TQVPSSILDL
     VDDHHGSTGG QTVRCTAEGT PLPDIEWMIC KDIKKCNNET SWTILANNVS NIITEIHSRD
     RSTVEGRVTF AKVEETIAVR CLAKNLLGAE NRELKLVAPT LRSELTVAAA VLVLLVIVII
     SLIVLVVIWK QKPRYEIRWR VIESISPDGH EYIYVDPMQL PYDSRWEFPR DGLVLGRVLG
     SGAFGKVVEG TAYGLSRSQP VMKVAVKMLK PTARSSEKQA LMSELKIMTH LGPHLNIVNL
     LGACTKSGPI YIITEYCFYG DLVNYLHKNR DSFLSHHPEK PKKELDIFGL NPADESTRSY
     VILSFENNGD YMDMKQADTT QYVPMLERKE VSKYSDIQRS LYDRPASYKK KSMLDSEVKN
     LLSDDNSEGL TLLDLLSFTY QVARGMEFLA SKNCVHRDLA ARNVLLAQGK IVKICDFGLA
     RDIMHDSNYV SKGSTFLPVK WMAPESIFDN LYTTLSDVWS YGILLWEIFS LGGTPYPGMM
     VDSTFYNKIK SGYRMAKPDH ATSEVYEIMV KCWNSEPEKR PSFYHLSEIV ENLLPGQYKK
     SYEKIHLDFL KSDHPAVARM RVDSDNAYIG VTYKNEEDKL KDWEGGLDEQ RLSADSGYII
     PLPDIDPVPE EEDLGKRNRH SSQTSEESAI ETGSSSSTFI KREDETIEDI DMMDDIGIDS
     SDLVEDSFL
//
